Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

Recruiting now · Phase 2

Conditions studied: Prostate Metastases

In brief

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Key facts

Study ID

NCT05656794

Run by

University Health Network, Toronto

People needed

40

Starts

2023-08-09

Expected to finish

2031-08-01

Last updated by the study team

2026-03-23

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-proven prostate cancer
• Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
• Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
• Planned for EBRT
• ECOG 0 or 1
• Age 18 years or older

You may not qualify if…

• Prior radiotherapy to pelvis
• Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
• Any condition where radiotherapy is contraindicated

Where it is running

• University Health Network, Princess Margaret Hospital — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.